AOD-9604: Fat-Burning Data in Mice, Not in People

The short version

AOD-9604 is a small, lab-made peptide copied from the tail end of human growth hormone — the part researchers believed was responsible for fat burning, without the parts that make bones and organs grow. The idea was a growth-hormone benefit (less body fat) without a growth-hormone side effect (elevated IGF-1, joint swelling, blood-sugar problems).

In mice, that idea worked: the fragment reduced body fat and switched on a fat-burning receptor (called beta-3 adrenergic receptor) in fat tissue ^[4][5]. In roughly six human trials totaling about 900 people, it was safe and easy to tolerate — about as gentle as a placebo ^[3]. But the number that actually mattered for a weight-loss drug — pounds lost against placebo — never became large enough to be statistically convincing, and the anti-obesity development program was discontinued. AOD-9604 also shows up in a small, separate line of joint-cartilage research ^[1], which this page covers too. Nothing here is a recommended dose or a treatment plan for a person.

What it is

AOD-9604 (also written AOD9604) is a synthetic hexadecapeptide — sixteen amino acids — modeled on residues 177-191 of human growth hormone, with an added N-terminal tyrosine standing in for the native phenylalanine. Its reported sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, and its two cysteines form an intramolecular disulfide bridge that mirrors the cystine loop found in the parent hormone. It was developed by Metabolic Pharmaceuticals as an oral anti-obesity candidate on the premise that this C-terminal fragment carries growth hormone's fat-metabolizing activity in isolation.

Pharmacokinetically, the molecule is short-lived: intravenous studies in animal models put its half-life at roughly three minutes, with degradation proceeding by sequential removal of N-terminal amino acids ^[2]. Despite that rapid turnover, oral absorption was demonstrated in a pig model, and non-clinical work found no genotoxic or toxicological red flags after chronic oral administration in rats and primates ^[2].

How it works

AOD-9604 does not bind the growth hormone receptor — that is the entire design premise. Instead, in rodent models it inhibits de novo lipogenesis (fat synthesis) by suppressing acetyl-CoA carboxylase, and it promotes fat oxidation through up-regulation of beta-3 adrenergic receptor (beta3-AR) expression in white adipose tissue ^[4]. A knockout-mouse study is the cleanest evidence for that mechanism: obese mice lacking a functional beta3-AR gene lost the chronic weight- and fat-reducing response to both intact human growth hormone and AOD-9604, while an acute increase in energy expenditure and fat oxidation persisted regardless of beta3-AR status — meaning the fragment's short-term metabolic bump and its longer-term fat-loss effect appear to run through at least partly separate pathways ^[4][5].

A smaller, unrelated line of research has tested AOD-9604 in a joint-cartilage context: weekly intra-articular injection in a rabbit model of collagenase-induced knee osteoarthritis reduced cartilage-degeneration scores versus saline over four to seven weeks ^[1]. That mechanism, if any, is distinct from the lipolytic pathway above and has not been tested in human joints.

What the research shows

Rodent fat-metabolism data. Two related 2001 studies in obese mice found that chronic treatment with either intact human growth hormone or the AOD-9604 fragment increased fat oxidation and produced measurable weight loss; in beta3-AR knockout mice, the chronic weight/fat effect was abolished while the acute energy-expenditure bump was preserved ^[4][5].

Non-clinical safety and pharmacokinetics. AOD-9604 was found free of genotoxic and toxicological concerns after chronic oral dosing in rats and primates, with an intravenous half-life of roughly three minutes and a degradation pathway of sequential N-terminal amino-acid removal; oral absorption was confirmed in a pig model ^[2].

Human safety and tolerability program. Across roughly six clinical trials totaling about 900 obese adults, oral AOD-9604 at daily doses from 0.25 mg to 54 mg over periods from seven days to 24 weeks produced a safety and tolerability profile indistinguishable from placebo, without the adverse effects associated with full-length growth hormone ^[3]. This program established safety, not efficacy — the weight-loss outcome did not reach a statistically significant advantage over placebo, and the anti-obesity development program was subsequently discontinued.

Cartilage model. In a collagenase-induced rabbit knee osteoarthritis model (n=32), weekly intra-articular AOD9604 — with or without hyaluronic acid — reduced gross and histopathological cartilage-degeneration scores relative to saline control over four to seven weeks ^[1]. This is a single preclinical model; no published human osteoarthritis trial of AOD-9604 exists.

Reported effects, cautions & safety

The community record around AOD-9604 is thinner and more mixed than for the incretin peptides on this desk, and it is offered here explicitly as anecdotal, not clinical evidence — unverified self-report from forums and research-use communities, not data from a monitored trial.

What people report noticing (anecdotal, not clinical evidence): the most consistent theme is being well tolerated with few day-to-day complaints, echoing the trial finding that side effects were hard to distinguish from placebo — and, relatedly, an absence of the water retention, joint puffiness, and tingling that some associate with raising IGF-1 through full growth hormone. A subset describe a mild lift in energy or mood, and some report eating a little less, though both are easily explained by concurrent diet changes rather than the peptide. Community lore about localized or 'spot' fat loss at the injection site is common but biologically implausible — no trial supports fat loss by injection location.

What people report not noticing (anecdotal, not clinical evidence): by far the most common report is the absence of any noticeable fat loss, which lines up with the human obesity trials failing to beat placebo. Reviewers frequently describe disappointment relative to the 'fat-burning peptide' marketing, and those who do report a visible change almost always attribute it to a calorie deficit and exercise running alongside the peptide, not the peptide itself. Occasional injection-site redness or irritation is reported, generically consistent with any subcutaneous injection rather than a drug-specific effect.

Cited cautions: AOD-9604 was developed as an oral anti-obesity candidate but never gained marketing approval anywhere, and it carries no approved indication or dosing standard, so any use outside a registered trial is experimental. Its mechanistic story — acetyl-CoA carboxylase inhibition, beta3-AR up-regulation, increased fat oxidation — was built almost entirely in mouse, rat, and cell models ^[4][5], and that rodent efficacy did not translate into a proven human fat-loss benefit is itself a documented example of preclinical promise failing to reach the clinic ^[4]. Human exposure data extend only to about 24 weeks ^[3], so little is known about longer use. Independent of AOD-9604 specifically, research-grade peptide vials from unregulated suppliers vary in purity and identity, meaning a reported effect, or the lack of one, may reflect the actual vial contents as much as the labeled molecule.

Where it fits in metabolic research

AOD-9604 sits at the edge of this desk's spectrum, not its center: a growth-hormone-derived compound whose rodent mechanism was clean and whose human efficacy trial was not. It is useful precisely as a contrast case — where retatrutide posted a -24.2% mean body-weight change in a 48-week Phase 2 obesity trial ^[9] and semaglutide built an entire regulatory footprint on repeated, large-scale weight-loss trials ^[16], AOD-9604's pivotal human program measured safety, found it favorable, and did not clear the efficacy bar. Reading it alongside the other three peptides on this desk is a reminder that a defensible mechanism and a clean safety record are necessary but not sufficient for a compound to earn a place in the approved-drug column. See the comparison page for the full picture across all four.